Trial Profile
Open Label Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Healthy Volunteers and Patients With Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2014
Price :
$35
*
At a glance
- Drugs AZD 2184 (Primary) ; Flutafuranol F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors AstraZeneca
- 07 Apr 2014 New trial record